Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $55.83.
A number of research firms recently weighed in on RYTM. Bank of America cut shares of Rhythm Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $49.00 to $42.00 in a research note on Wednesday, May 8th. Canaccord Genuity Group lowered their target price on shares of Rhythm Pharmaceuticals from $80.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Wells Fargo & Company lowered their target price on shares of Rhythm Pharmaceuticals from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Thursday, April 18th. Finally, Needham & Company LLC upped their target price on shares of Rhythm Pharmaceuticals from $46.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday.
Read Our Latest Analysis on Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Stock Performance
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($2.35) EPS for the quarter, missing analysts’ consensus estimates of ($2.34) by ($0.01). The company had revenue of $26.00 million for the quarter, compared to analyst estimates of $26.90 million. Rhythm Pharmaceuticals had a negative net margin of 297.91% and a negative return on equity of 179.26%. The firm’s quarterly revenue was up 126.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.92) EPS. As a group, equities analysts forecast that Rhythm Pharmaceuticals will post -4.45 earnings per share for the current year.
Insiders Place Their Bets
In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 3,984 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $38.47, for a total transaction of $153,264.48. Following the sale, the insider now directly owns 30 shares of the company’s stock, valued at $1,154.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 19,765 shares of company stock valued at $973,772. 5.60% of the stock is currently owned by insiders.
Institutional Trading of Rhythm Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC increased its holdings in shares of Rhythm Pharmaceuticals by 62.6% in the second quarter. CWM LLC now owns 657 shares of the company’s stock valued at $27,000 after purchasing an additional 253 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Rhythm Pharmaceuticals by 4.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,181 shares of the company’s stock valued at $422,000 after purchasing an additional 406 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Rhythm Pharmaceuticals by 91.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,256 shares of the company’s stock valued at $58,000 after purchasing an additional 600 shares in the last quarter. American International Group Inc. increased its holdings in shares of Rhythm Pharmaceuticals by 3.1% in the first quarter. American International Group Inc. now owns 26,318 shares of the company’s stock valued at $1,140,000 after purchasing an additional 781 shares in the last quarter. Finally, AJOVista LLC acquired a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter valued at approximately $42,000.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Further Reading
- Five stocks we like better than Rhythm Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Do S&P 500 Stocks Tell Investors About the Market?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What is the Nikkei 225 index?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.